North America Biopharmaceutical Contract Manufacturing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Biologics and Biosimilar), Service (Process Development, Fill and Finish Operation, Analytical and QC Studies, and Packaging), and Source (Mammalian and Microbial-Based Biologics/Non-Mammalian)
The biopharmaceutical contract manufacturing market in North America is expected to grow from US$ 7,127.97 million in 2021 to US$ 12,847.38 million by 2028; it is estimated to register a CAGR of 8.8% from 2021 to 2028.
The contract manufacturing organization (CMO) offers many benefits to pharmaceutical companies, including reducing investments in facilities and drug development costs, thereby improving net cash flow. Outsourcing is cheaper and enhances the efficiency of manufacturing processes. It allows pharmaceutical & biotechnology companies to redirect resources to other areas. In the past few years, the contract manufacturing industry was a niche service market offering more manufacturing capacity or specific services to pharmaceutical companies. The rise of CMOs was fueled by the rising number of drug manufacturing failures. Pharmaceutical companies undertook many manufacturing facilities to develop innovative drugs in the past. However, the demand for manufacturing outsourcing has continuously risen to reduce the risk of overcapacities. Moreover, several pharmaceutical companies are refocusing on their core capabilities, such as research and development, leading to divestments of in-house manufacturing capacities, further growing reliance on CMOS for manufacturing. Furthermore, the CMOs are vital in providing additional benefits to mitigate the risk of supply shortages by offering various sites for pharmaceutical companies with multisite supply strategies and backup capacities. For instance, in 2019, Samsung Biologics and GI Innovation signed a contract for immunochemotherapy. Under this agreement, Samsung Biologics provided services ranging from f-cell lines development to the production of phase-I drug substances. Therefore, the rising outsourcing of development, manufacturing, fill and finish, and packaging operations to contract manufacturing companies are expected to create significant market opportunities for market players, leading to the subsequent growth of the biopharmaceutical contract manufacturing market.
North America Biopharmaceutical Contract Manufacturing Market Revenue and Forecast to 2028 (US$ Million)
Get more information on this report :
North America Biopharmaceutical Contract Manufacturing Market Segmentation
North America Biopharmaceutical Contract Manufacturing Market – By Product
- Biologics
- Monoclonal Antibodies
- Recombinant Proteins
- Vaccines
- Others
- Biosimilar
North America Biopharmaceutical Contract Manufacturing Market – By Service
- Process Development
- Downstream Processing
- Upstream Processing
- Fill and Finish Operation
- Analytical and QC Studies
- Packaging
North America Biopharmaceutical Contract Manufacturing Market – By Source
- Mammalian
- Microbial-Based Biologics/ Non-Mammalian
North America Biopharmaceutical Contract Manufacturing Market– By Country
- The US
- Canada
- Mexico
North America Biopharmaceutical Contract Manufacturing Market-Companies Mentioned
- AbbVie Inc.
- Ajinomoto Co. Inc
- Boehringer Ingelheim International GmbH
- General Electric Company
- Lonza
- MERCK KGAA
- Samsung Biologics
- THERMO FISHER SCIENTIFIC INC
- WUXI BIOLOGICS
1. Introduction
1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Biopharmaceutical Contract Manufacturing Market – By Product
1.3.2 North America Biopharmaceutical Contract Manufacturing Market – By Service
1.3.3 North America Biopharmaceutical Contract Manufacturing Market – By Source
1.3.4 North America Biopharmaceutical Contract Manufacturing Market – By Country
2. North America Biopharmaceutical Contract Manufacturing Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Biopharmaceutical Contract Manufacturing – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America – PEST Analysis
4.3 Expert Opinion
5. North America Biopharmaceuticals Contract Manufacturing Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Outsourcing by Pharmaceutical Companies
5.1.2 Increasing Demand for Biologics
5.2 Market Restraints
5.2.1 Growing Competition in Industry
5.3 Future Trends
5.3.1 Consolidation in Pharmaceutical CMO Industry
5.3.2 COVID-19 Pandemic
5.4 Impact Analysis
6. Biopharmaceutical Contract Manufacturing Market – North America Analysis
6.1 North America Biopharmaceutical Contract Manufacturing Market Revenue Forecast and Analysis
7. North America Biopharmaceuticals Contract Manufacturing Market Analysis – By Product
7.1 Overview
7.2 North America Biopharmaceuticals Contract Manufacturing Market Revenue Share, by Product (2021 and 2028)
7.3 Biologics
7.3.1 Overview
7.3.2 Biologics: North America Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.1 Monoclonal Antibodies
7.3.2.1.1 Overview
7.3.2.1.2 Monoclonal Antibodies: North America Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.2 Recombinant Proteins
7.3.2.2.1 Overview
7.3.2.2.2 Recombinant Proteins: North America Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.3 Vaccines
7.3.2.3.1 Overview
7.3.2.3.2 Vaccines: North America Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.4 Others
7.3.2.4.1 Overview
7.3.2.4.2 Others: North America Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Biosimilar
7.4.1 Overview
7.4.2 Biosimilar: North America Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (US$ Million)
8. North America Biopharmaceuticals Contract Manufacturing Market – By Service
8.1 Overview
8.2 North America Biopharmaceuticals Contract Manufacturing Market, by Service, 2021 and 2028 (%)
8.3 Process Development
8.3.1 Overview
8.3.2 Process Development: North America Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (US$ Million)
8.3.2.1 Downstream Processing
8.3.2.1.1 Overview
8.3.2.1.2 Downstream Processing: North America Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (US$ Million)
8.3.2.2 Upstream Processing
8.3.2.2.1 Overview
8.3.2.2.2 Upstream Processing: North America Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Fill and Finish Operations
8.4.1 Overview
8.4.2 Fill and Finish Operations: North America Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Analytical and QC Studies
8.5.1 Overview
8.5.2 Analytical and QC Studies: North America Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Packaging
8.6.1 Overview
8.6.2 Packaging: North America Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (US$ Million)
9. North America Biopharmaceuticals Contract Manufacturing Market – By Source
9.1 Overview
9.2 North America Biopharmaceuticals Contract Manufacturing Market, by Source, 2021 and 2028 (%)
9.3 Mammalian
9.3.1 Overview
9.3.2 Mammalian: North America Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Microbial/Non-Mammalian-Based Biologics
9.4.1 Overview
9.4.2 Microbial/Non-Mammalian-Based Biologics: North America Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (US$ Million)
10. North America Biopharmaceutical Contract Manufacturing Market – Country Analysis
10.1 North America: Biopharmaceutical Contract Manufacturing Market
10.1.1 Overview
10.1.2 North America: Biopharmaceutical Contract Manufacturing Market, by Country, 2021 & 2028 (%)
10.1.2.1 US: Biopharmaceutical Contract Manufacturing Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.1.1 US: Biopharmaceutical Contract Manufacturing Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.1.2 US: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
10.1.2.1.2.1 US: Biologics Market, 2019-2028 (USD Million)
10.1.2.1.3 US: Biopharmaceutical Contract Manufacturing Market, by Service, 2019–2028 (USD Million)
10.1.2.1.3.1 US: Process Development Market, 2019-2028 (USD Million)
10.1.2.1.4 US: Biopharmaceutical Contract Manufacturing Market, by Source, 2019–2028 (USD Million)
10.1.2.2 Canada: Biopharmaceutical Contract Manufacturing Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.2.1 Canada: Biopharmaceutical Contract Manufacturing Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.2.2 Canada: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
10.1.2.2.2.1 Canada: Biologics Market, 2019-2028 (USD Million)
10.1.2.2.3 Canada: Biopharmaceutical Contract Manufacturing Market, by Service, 2019–2028 (USD Million)
10.1.2.2.3.1 Canada: Process Development Market, 2019-2028 (USD Million)
10.1.2.2.4 Canada: Biopharmaceutical Contract Manufacturing Market, by Source, 2019–2028 (USD Million)
10.1.2.3 Mexico: Biopharmaceutical Contract Manufacturing Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.3.1 Mexico: Biopharmaceutical Contract Manufacturing Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.3.2 Mexico: Biopharmaceutical Contract Manufacturing Market, by Product, 2019-2028 (USD Million)
10.1.2.3.2.1 Mexico: Biologics Market, 2019-2028 (USD Million)
10.1.2.3.3 Mexico: Biopharmaceutical Contract Manufacturing Market, by Service, 2019–2028 (USD Million)
10.1.2.3.3.1 Mexico: Process Development Market, 2019-2028 (USD Million)
10.1.2.3.4 Mexico: Biopharmaceutical Contract Manufacturing Market, by Source, 2019–2028 (USD Million)
11. North America Biopharmaceutical Contract Manufacturing Market – Industry Landscape
11.1 Overview
11.2 Organic Developments
11.2.1 Overview
11.3 Inorganic Developments
11.3.1 Overview
12. Company Profiles
12.1 Boehringer Ingelheim International GmbH
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 THERMO FISHER SCIENTIFIC INC.
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 General Electric Company
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 MERCK KGAA
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Lonza
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Samsung Biologics
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 AbbVie Inc.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 WUXI BIOLOGICS
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Ajinomoto Co. Inc.
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Biopharmaceutical Contract Manufacturing Market –Revenue and Forecast to 2028 (US$ Million)
Table 2. US Biopharmaceutical Contract Manufacturing Market, by Product– Revenue and Forecast to 2028 (USD Million)
Table 3. US Biologics Market – Revenue and Forecast to 2028 (USD Million)
Table 4. US Biopharmaceutical Contract Manufacturing Market, by Service – Revenue and Forecast to 2028 (USD Million)
Table 5. US Process Development Market – Revenue and Forecast to 2028 (USD Million)
Table 6. US Biopharmaceutical Contract Manufacturing Market, by Source – Revenue and Forecast to 2028 (USD Million)
Table 7. Canada Biopharmaceutical Contract Manufacturing Market, by Product– Revenue and Forecast to 2028 (USD Million)
Table 8. Canada Biologics Market – Revenue and Forecast to 2028 (USD Million)
Table 9. Canada Biopharmaceutical Contract Manufacturing Market, by Service – Revenue and Forecast to 2028 (USD Million)
Table 10. Canada Process Development Market – Revenue and Forecast to 2028 (USD Million)
Table 11. Canada Biopharmaceutical Contract Manufacturing Market, by Source – Revenue and Forecast to 2028 (USD Million)
Table 12. Mexico Biopharmaceutical Contract Manufacturing Market, by Product– Revenue and Forecast to 2028 (USD Million)
Table 13. Mexico Biologics Market – Revenue and Forecast to 2028 (USD Million)
Table 14. Mexico Biopharmaceutical Contract Manufacturing Market, by Service – Revenue and Forecast to 2028 (USD Million)
Table 15. Mexico Process Development Market – Revenue and Forecast to 2028 (USD Million)
Table 16. Mexico Biopharmaceutical Contract Manufacturing Market, by Source – Revenue and Forecast to 2028 (USD Million)
Table 17. Organic Developments Done By Companies
Table 18. Inorganic Developments Done By Companies
Table 19. Glossary of Terms, North America Biopharmaceutical Contract Manufacturing Market
LIST OF FIGURES
Figure 1. North America Biopharmaceutical Contract Manufacturing Market Segmentation
Figure 2. North America Biopharmaceutical Contract Manufacturing Segmentation, By Country
Figure 3. North America Biopharmaceutical Contract Manufacturing Market Overview
Figure 4. Biologics Segment Held Largest Share Of Product In North America Biopharmaceutical Contract Manufacturing Market
Figure 5. US Is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. North America PEST Analysis
Figure 7. North America Biopharmaceutical Contract Manufacturing Market Impact Analysis of Drivers and Restraints
Figure 8. North America Biopharmaceutical Contract Manufacturing Market – Revenue Forecast and Analysis – 2020 - 2028
Figure 9. North America Biopharmaceuticals Contract Manufacturing Market Revenue Share, by Product (2021 and 2028)
Figure 10. Biologics: North America Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 11. Monoclonal Antibodies: North America Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Recombinant Proteins: North America Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Vaccines: North America Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Others: North America Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. Biosimilar: North America Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. North America Biopharmaceuticals Contract Manufacturing Market, by Service, 2021 and 2028 (%)
Figure 17. Process Development: North America Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. Downstream Processing: North America Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. Upstream Processing: North America Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. Fill and Finish Operations: North America Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. Analytical and QC Studies: North America Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. Packaging: North America Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. North America Biopharmaceuticals Contract Manufacturing Market, by Source, 2021 and 2028 (%)
Figure 24. Mammalian: North America Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Microbial/Non-Mammalian-Based Biologics: North America Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. North America: Biopharmaceutical Contract Manufacturing Market, by Key Country – Revenue (2021) (USD Million)
Figure 27. North America: Biopharmaceutical Contract Manufacturing Market, by Country, 2021 & 2028 (%)
Figure 28. US: Biopharmaceutical Contract Manufacturing Market – Revenue and Forecast to 2028 (USD Million)
Figure 29. Canada: Biopharmaceutical Contract Manufacturing Market – Revenue and Forecast to 2028 (USD Million)
Figure 30. Mexico: Biopharmaceutical Contract Manufacturing Market – Revenue and Forecast to 2028 (USD Million)
- AbbVie Inc.
- Ajinomoto Co. Inc
- Boehringer Ingelheim International GmbH
- General Electric Company
- Lonza
- MERCK KGAA
- Samsung Biologics
- THERMO FISHER SCIENTIFIC INC
- WUXI BIOLOGICS
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America Biopharmaceutical Contract Manufacturing Market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the North America Biopharmaceutical Contract Manufacturing Market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the Biopharmaceutical Contract Manufacturing Market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution